Results 31 to 40 of about 303,717 (280)
BMC Neurology, 2021 Background Interleukin-6-receptor inhibitors like Tocilizumab and Satralizumab are showing promising results in the treatment of Neuromyelitis Optica spectrum disorder (NMOSD).
Sanjeev Kharel +4 more
doaj +1 more source
Modifying effect of a common polymorphism in the interleukin-6 promoter on the relationship between long-term exposure to traffic-related particulate matter and heart rate variability [PDF]
, 2014 Exposure to particulate matter (PM) has been associated with an increase in many inflammatory markers, including interleukin 6 (IL6). Air pollution exposure has also been suggested to induce an imbalance in the autonomic nervous system (ANS), such as a ...
Probst-Hensch, Nicole +19 more
core +1 more source
A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease [PDF]
Clinical and Experimental Immunology, 2005 SummaryThe presence and the role of soluble gp130, the soluble form of a component of the interleukin (IL)-6 receptor complex, were investigated in inflammatory bowel disease. The serum concentrations of soluble gp130 were increased in ulcerative colitis (active disease, median, 93·5 ng/ml; interquartile range, 26–125 ng/ml; inactive disease, 81 ng/ml,
K, Mitsuyama +10 more
openaire +2 more sources
AB0470 EXPERIENCE WITH THE USE OF INTERLEUKIN 6 INHIBITOR IN SEVERE ANKYLOSING SPONDYLITIS [PDF]
Annals of the Rheumatic Diseases, 2021 Background: Inhibitors of interleukin 6 (IL6) have been found to be ineffective in ankylosing spondylitis (AS) based on the results of randomized clinical trials (RCTs) on tocilizumab (TCZ) and sarilimumab [1, 2]. However, there is evidence that IL6 is actively involved in the pathogenesis of the disease [3].
D. Rumiantceva +3 more
openaire +1 more source
The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis [PDF]
Modern Rheumatology, 2019 Systemic sclerosis (SSc) is a connective tissue disease, the pathogenesis of which is thought to involve interleukin-6 (IL-6), an inflammatory cytokine. This is based on findings of its concentration in patient serum, the results of an IL-6 suppression experiment in an animal model, and the results of a pilot study using IL-6 receptor antibody. However,
openaire +2 more sources
Clinical, Cosmetic and Investigational Dermatology, 2023 Xiaojing Zhong,* Tongtong Xu,* Tianhao Li,* Nana Luo, Nan Luo, Pingsheng Hao Author Affiliations Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China*These authors ...
Zhong X, Xu T, Li T, Luo N, Luo N, Hao P
doaj
, 2003 Interleukin-18 (IL-18), a recently described member of the IL-1 cytokine superfamily, is now recognized as an important regulator of innate and acquired immune responses.
McInnes, I.B. +2 more
core +1 more source
Научно-практическая ревматология, 2019 The review summarizes current idea on the key role of interleukin 6 (IL-6) in the pathogenesis of rheumatic diseases (RDs) and depressive disorders. It considers in detail the mechanisms by which IL6 induces the clinical and laboratory manifestations of ...
T. A. Lisitsyna +3 more
doaj +1 more source
The onset of labor alters corticotropin-releasing hormone type 1 receptor variant expression in human myometrium : putative role of interleukin-1ß [PDF]
, 2007 CRH targets the human myometrium during pregnancy. The efficiency of CRH actions is determined by expression of functional receptors (CRH-R), which are dynamically regulated.
Gu, Mei +6 more
core +1 more source
The Tohoku Journal of Experimental Medicine, 2022 Immune checkpoint inhibitors (ICIs) have proven clinical benefits in various advanced cancers. However, despite their significant therapeutic efficacy, ICIs induce immune-related adverse events. Among these events, autoimmune meningoencephalitis often has severe effects on patients' outcomes, but its specific clinical features are still unclear.
Mizukami, Takeshi +6 more
openaire +2 more sources